Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EDNRB | P24530 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8343522 | 0.82 | LMNA (0.45) | PDE2ASLC6A3LMNASMN1; SMN2KDM4E | |
| SCHEMBL6826219 | 0.78 | SMN1; SMN2 (0.36) | PDE2ASLC6A3LMNASMN1; SMN2KDM4E | |
| SCHEMBL10272807 | 0.75 | SLC6A3 (0.48) | PDE2ASLC6A3LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL15274617 | 0.75 | PDE2A (0.48) | PDE2ANOS3NOS1NOS2LMNA | |
| SCHEMBL17995540 | 0.75 | ESR1 (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL799392 | 0.75 | LMNA (0.47) | PDE2ANOS3NOS1NOS2LMNA | |
| SCHEMBL22576253 | 0.73 | ALDH1A1 (0.42) | PDE2ANOS3NOS1NOS2LMNA | |
| SCHEMBL12015842 | 0.73 | NPC1 (0.47) | NOS3NOS1NOS2LMNASMN1; SMN2 | |
| SCHEMBL2716657 | 0.73 | NOS2 (0.52) | NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL1759758 | 0.71 | TDP1 (0.62) | LMNAKDM4EALDH1A1L3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | PDE2A 763/4885SLC6A3 1363/4885NOS3 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.